GMMG-DANTE: DVd in patients with multiple myeloma and renal impairment

Causes & management of renal impairment in patients with multiple myelomaПодробнее

The impact of renal impairment on the MM treatment strategyПодробнее

Managing patients with 'difficult-to-treat' myelomaПодробнее

Dr. Noopur Raje Discusses Kidney Disease in Multiple MyelomaПодробнее

Managing and treating renal impairment in multiple myelomaПодробнее

Managing renal failure in patients with multiple myelomaПодробнее

MYELOMA UNIVERSITY | Learn about renal (kidney) impairment in patients with multiple myeloma.Подробнее

Dara plus dex in R/R myeloma patients with renal impairmentПодробнее

Factors affecting renal response in myeloma with acute renal failure due to cast nephropathyПодробнее

Using real-world data to optimize treatment in patients with multiple myelomaПодробнее

Digital Infoday Session - Myeloma and the kidneyПодробнее

Renal complications in multiple myeloma - trials and next stepsПодробнее

DPd against DVd for daratumumab-naïve patients with R/R multiple myelomaПодробнее

DARE: dara for R/R myeloma with renal impairmentПодробнее

Renal complications in multiple myeloma - characteristics and treatmentПодробнее

How effective are current drug treatments for patients with myeloma kidney disease?Подробнее

Efficacy of VenDd vs DVd in patients with t(11;14) R/R myelomaПодробнее

Denosumab in multiple myeloma patients with renal insufficiencyПодробнее

GMMG-HD4 and MM5: bortezomib vs. lenalidomide for myeloma maintenanceПодробнее